This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The non hormonal contraceptives market is estimated to be worth $1.8 billion in 2021 and is expected to grow at CAGR of 22% during the forecast period. According to the World Health Organization (WHO), sexual and reproductive health-related conditions represent around one third of all clinical conditions prevalent among women between the ages of 15 and 44 years. The human female reproductive system is complex and governed primarily by two hormones, estrogen and progesterone. Since hormones are r...

The global biologics contract research organization market size, valued at USD 27.0 billion in 2024, is projected to reach USD 36.0 billion in 2025 and USD 126.0 billion by 2035, representing a CAGR of 13% during the forecast period. According to the biologics contract research organization market report, presently the antibodies segment holds the highest share (45%), and the trend is likely to remain unchanged. Among these, the clinical segment holds the largest biologics contract research orga...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The global continuous manufacturing systems market is estimated to grow from USD 378 million in 2025 to reach USD 483 million in 2026 and USD 1,750 million by 2035, representing a higher CAGR of 15.4% during the forecast period. Given the ever-increasing demand for pharmacological interventions, and the introduction of new and sophisticated therapeutic modalities, drug substance manufacturers are gradually opting for more advanced manufacturing solutions, such as continuous flow reactor. When co...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The cold chain logistics market, valued at USD 4.13 billion in 2025, is projected to reach USD 4.18 billion in 2026 and USD 4.32 billion by 2030, with a 0.85% CAGR during the forecast period 2026 to 2030. Over 95% of all approved biologics and 90% of all vaccines are cold chain dependent. According to the data presented by the WHO, the current global vaccination coverage is nearly 85%; however, it has been reported that 25% of vaccines are damaged due to cold chain malfunction (improper distrib...

The global immunocytokines market, valued at USD 847 million in 2025, is projected to reach USD 1,514 million in 2026 and USD 5,374 million by 2030, with a 37.3% CAGR during the forecast period 2026 to 2030. It is worth mentioning that cancer is one of the leading causes of death worldwide, accounting for an estimated 0.6 million deaths in 2020, in the US alone. In fact, WHO has estimated the number of new cancer cases to rise by 70%, worldwide, over the next 20 years. However, amongst the emer...

The global real world evidence solutions market, valued at USD 2.2 billion in 2025, is projected to reach USD 2.6 billion in 2026 and USD 4.5 billion by 2030, with a 15.1% CAGR during the forecast period, 2026 to 2030. It is also well known that clinical research is fraught with various other challenges, including inefficiencies in medical data management and processing, unforeseen delays, risk of failure / study termination and several clinical trial patient recruitment services and retention-r...

The global antibody purification services market, valued at USD 1.30 billion in 2025, is projected to reach USD 1.42 billion in 2026 and USD 2.02 billion by 2030, representing a CAGR of 9.2% during the forecast period. With the surge in demand for antibodies across research, diagnostic and therapeutic applications, there is now an urgent, parallel need to optimize production throughput. In this context, the purification aspect needs to be handled with extra caution, considering the dangers assoc...

The global antisense oligonucleotides market, valued at USD 5.78 billion in 2025, is projected to reach USD 6.31 billion in 2026 and USD 8.57 billion by 2035, with a 8.0% CAGR during the forecast period 2026 to 2035. Since the approval of Vitravene™ (for the treatment of cytomegalovirus retinitis) in 1998, antisense oligonucleotide (ASO) therapies have evolved into a prominent class of therapeutics. In addition to the seven antisense oligonucleotides drugs, based on such molecules, that are co...

The medical batteries market, valued at USD 1.64 billion in 2025, is projected to grow to USD 1.85 billion in 2026 and USD 3.10 billion by 2030, representing a CAGR of 13.8% during the forecast period. The exponential growth in wearable medical devices and implants, such as hearing aids, implantable cardiac defibrillators, infusion pumps, neurostimulators and pacemakers, has led to an increase in demand for safe, compact, lightweight and high energy density batteries with better cycle life. Desp...

The portable x ray devices market is estimated to be worth $900 million in 2021 and is expected to grow at CAGR of 13% during the forecast period. Since the discovery of X-rays, the field of medical imaging has evolved significantly, offering a non-invasive means for physicians to accurately visualize almost all major organ systems for diagnostic purposes. Presently, there are a number of handheld X-ray imaging devices available in the market, and several device developers are engaged in efforts...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The automated cell processing system market is estimated to be worth $220 million in 2020 and is expected to grow at CAGR of 16% during the forecast period. Over the past two decades, more than 30 ATMPs have been approved. Moreover, according to a recent report (published by The Alliance for Regenerative Medicine), over 1,050 clinical trials are currently being conducted by over 1,000 companies, worldwide, focused on the evaluation of cell and gene therapies. However, these cell therapies are ex...